Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?

[Image: see text] SARS-CoV-2 encoded papain-like protease (PLpro) harbors a labile Zn site (Cys(189)–X–X–Cys(192)–X(n)–Cys(224)–X–Cys(226)) and a classic catalytic site (Cys(111)–His(272)–Asp(286)), which play key roles for viral replication and hence represent promising drug targets. In this Viewpo...

Descripción completa

Detalles Bibliográficos
Autor principal: Maiti, Biplab K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409920/
https://www.ncbi.nlm.nih.gov/pubmed/33062954
http://dx.doi.org/10.1021/acsptsci.0c00093
Descripción
Sumario:[Image: see text] SARS-CoV-2 encoded papain-like protease (PLpro) harbors a labile Zn site (Cys(189)–X–X–Cys(192)–X(n)–Cys(224)–X–Cys(226)) and a classic catalytic site (Cys(111)–His(272)–Asp(286)), which play key roles for viral replication and hence represent promising drug targets. In this Viewpoint, both sulfur-based drugs and peptides-based inhibitors may block Cys residues in the catalytic and/or Zn site of CoV-2-PLpro, leading to dysfunction of CoV-2-PLpro and thereby halting viral replication.

Ejemplares similares